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ABSTRACT
Objective The PREDICT-PD study aims to identify
increased risk of Parkinson’’s disease (PD) using online
assessments of previously identiﬁed risk and early
features of PD and an evidence-based scoring algorithm.
We sought to determine whether higher risk participants
(deﬁned as those above the 15th centile of risk
estimates) were more likely to have mild parkinsonian
signs compared with lower risk participants.
Methods Video recordings of neurological
examinations, including the Movement Disorder Society
Uniﬁed Parkinson’s Disease Rating Scale (MDS-UPDRS)
part III, of 208 individuals who had previously
completed an online risk assessment were scored blindly
and independently by two movement-disorders experts.
Higher risk and lower risk subjects were compared for
MDS-UPDRS part III score (and derivations of this) to
identify subclinical parkinsonism, and association of risk
estimates with MDS-UPDRS III scores assessed.
Results Higher risk subjects had signiﬁcantly higher
median UPDRS part III scores (3, IQR 1–5.5) than
lower risk subjects (1, IQR 0–3.0; p<0.001), and there
was a signiﬁcantly greater proportion of individuals
classiﬁed as having subclinical parkinsonism. 18% of the
higher risk subjects and 6% of the lower risk subjects
exceeded the most stringent published cut-off for
subtle parkinsonism of three deﬁnitions examined
(p=0.027). Linear regression analysis demonstrated a
continuous relationship of log-transformed risk estimates
with UPDRS part III scores (increase in MDS-UPDRS
per doubling of odds 0.52, 95% CI 0.31 to 0.72;
p<0.001), which remained after adjustment for multiple
vascular risk factors and scores on the Montreal
Cognitive Assessment (0.58, 95% CI 0.30 to 0.87;
p<0.001).
Conclusions The PREDICT-PD algorithm identiﬁes a
population with an increased rate of motor disturbances.
INTRODUCTION
Despite signiﬁcant advances in the ﬁeld of
Parkinson’’s disease (PD), it remains incurable and
causes signiﬁcant morbidity. The pathological
process, leading to neuronal death in the substantia
nigra pars compacta, begins years before motor
disturbance causes functional handicap.1 Earlier
detection could pave the way for clinical trials of
treatments in individuals at greater risk of develop-
ing the disease.2
In the ‘prodromal phase’ or ‘prediagnostic
phase’, there may be transient or subtle motor dys-
function, in parallel with non-motor features, prior
to diagnosis.3–8 Subtle parkinsonian signs are
common in older persons with an estimated preva-
lence of 30–40%.9 10 While non-progression is a
feature in some, their presence can herald cognitive
decline or other adverse health outcomes, including
frailty and death.11 12
PREDICT-PD is a UK population-based cohort
study which aims to identify individuals in the pre-
diagnostic phase of PD using online assessments
and an evidence-based algorithm. At baseline,
PREDICT-PD recruited 1323 participants to com-
plete online surveys, the answers to which yielded a
combined risk estimate of PD. Participants were
ranked from highest to lowest risk and a variety of
comparative analyses undertaken between the
extremes of risk.13 We here examined whether this
approach can identify individuals with subtle motor
features indicative of prodromal PD.
METHODS
The cohort was established in 2011 and the
method of volunteer recruitment has been previ-
ously published.13 In brief, volunteers were indivi-
duals over the age of 60 years, without known
neurological disease and residing in the UK. They
completed an online consent form, questionnaire
and keyboard-tapping test, and were sent the
University of Pennsylvania Smell Identiﬁcation Test
(UPSIT) by post.14 15 All aspects of the study were
carried out in accordance with the Declaration of
Helsinki and were approved by the Queen Square
Ethics Committee (reference number 10/H0716/
85). Baseline inclusion and exclusion criteria are
presented in the online supplementary material.
Online assessments
Every year participants answered an annual online
survey and their risk of PD was estimated in
accordance with responses. Estimates were based
on previously identiﬁed factors, described in a sys-
tematic review and meta-analysis.16 Cross-sectional
analyses have compared higher risk subjects
(deﬁned as those above the 15th centile of risk esti-
mates), with lower risk subjects (participants with
risk estimates below the 85th centile) in terms of
objective smell and ﬁnger tapping, as well as sub-
jective REM-sleep behaviour disorder (RBD).13
Detailed methods are described in the online
supplementary material.
Clinical examinations
From 2012, selected participants consented to a
home visit, to determine whether the higher risk
participants were more likely to have subtle motor
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features of PD compared with lower risk subjects. Participants
were sampled with a preference for those estimated to be at
the highest risk. Lower risk subjects (and middle risk) were
required for comparative analysis and also to maintain blinding
of participants to risk (for distribution of risk scores see online
supplementary ﬁgure 1). Geographical location did not bias
assessment and participants were seen regardless of where they
resided in the UK. Acceptance rates to telephone invitations
for home visits are provided in the online supplementary
table S1.
During the domiciliary visit, a neurological examination was
carried out by a trained clinician (AJN), including the
Movement Disorder Society Uniﬁed Parkinson’’s Disease Rating
Scale (MDS-UPDRS) motor section (part III), which was
recorded on video (all reference to MDS-UPDRS throughout the
manuscript refers to part III motor scores only).17 During the
same visit, participants were assessed with the Montreal
Cognitive Assessment (MoCA), which has been widely used as a
cognitive screening tool.18
Video scoring
Two senior movement disorders experts (AJL and AS), who
were blind to risk estimates and were provided with no add-
itional information about participants, independently scored the
participant videos using the MDS-UPDRS.17 Rigidity scores
were provided for each participant from the examination by
AJN, given that this could not be ascertained from watching the
videos. After all videos were scored, marks were compared
between raters. Where no signiﬁcant disparity existed between
individual raters’ scores (<5 point difference on the
MDS-UPDRS), the scores from both were averaged. Where
there was disparity in scores (≥5 points), the raters were asked
to rescore again independently. If signiﬁcant disparity remained,
the raters rescored jointly to obtain a consensus score.
The original version of the UPDRS can be used to calculate
an abbreviated score of ‘Mild Parkinsonian Signs’ (MPS). The
most widely used version is that developed by Louis et al10 19
(for details on scoring see online supplementary material).
Bradykinesia does not feature in the MPS score, because its
presence is an essential feature in the diagnostic criteria for
PD.20 We therefore included bradykinesia as an additional
outcome, considering bradykinesia as deﬁnite when combined
scores from the MDS-UPDRS bradykinesia items (ﬁnger
tapping, hand movements, hand pronation/supination, toe
tapping and leg agility) were ≥1.5. We used a second deﬁnition
of MPS or subthreshold parkinsonism described recently by an
MDS Task Force, with scores >6 on the MDS-UPDRS (exclud-
ing action and postural tremor) indicating subthreshold
parkinsonism.3
In addition to these two UPDRS-based scores, raters were
asked to give a ‘global impression’ comment. After all videos
had been rated, these comments were coded as the following
ordered categorical variables: 0—normal, 1—minor clinical
abnormality not necessarily associated with PD, 2—subtle clin-
ical observation associated with PD, 3—suspected/possible
early PD/parkinsonism, and 4—probable PD based on the
Queen Square Brain Bank for Neurological Disorders diagnos-
tic criteria.20 Again, these global impression scores were aver-
aged for the two raters. Consensus was sought for ‘suspected’
or ‘probable’ PD (scores of 3 or 4). Cut-offs for our ‘global
impression’ score were as follows: scores ≤1.0 considered as
not indicative of parkinsonism, scores 1.5 to 2.5 indicative of
subtle parkinsonism and ≥3.0 considered as clear evidence of
parkinsonism.
Statistical analysis
The aim of the study was to test the null hypothesis of no differ-
ence between the higher compared with lower (combined
middle and lowest risk) risk subjects in the frequency and sever-
ity of motor dysfunction as assessed on the blinded ratings of
the video recordings. Risk scores were calculated and higher
risk and lower risk groups were calculated as described previ-
ously using the year 1 online assessment as this was closest to
the home visits in the majority of cases.13
First, the scores from the raters were compared using intra-
class correlation coefﬁcients (ICC) and Bland-Altman plots,
along with measures of bias and agreement. Where there was
substantial disparity, measures were taken to obtain consensus
before ﬁnal scores were analysed (see above).
Second, the representativeness of sampled participants com-
pared with the overall cohort was examined. Higher risk as well
as lower risk participants that had been seen were compared
with those not seen in terms of age, gender and other demo-
graphic information used for risk stratiﬁcation, as well as MoCA
scores, smell test scores and measures of motor function as
described above.
Analyses using continuous and categorical motor outcomes
were undertaken comparing higher risk subjects with lower risk
subjects, using t-tests for parametric and Wilcoxon Rank Sum
tests for non-parametric continuous data, Fisher’s exact test for
binary data, and the χ2 test for trend for ordinal data.
Linear regression was used to analyse the relationship of con-
tinuous risk estimates with MDS-UPDRS (excluding action and
postural tremor) using the log odds of PD. Multivariate linear
regression was undertaken to examine the inﬂuence of potential
confounding factors such as prevalent cognitive impairment
(using MoCA scores) and factors that increase risk of cerebro-
vascular disease. Vascular risk factors included: self-reported
diabetes or use of antidiabetic drugs, hypertension or use of
antihypertensives (ACE inhibitors, angiotensin receptor blockers
(ARBs), calcium channel blockers (CCBs), β-blockers and diure-
tics), hypercholesterolaemia or use of statins, ischaemic heart
disease and current smoking.
Age and gender were felt likely to confound the relationship
between risk and motor outcomes, but their signiﬁcant weight-
ing in the algorithm meant that adjusting could lead to multicol-
linearity and increased standard error. Hence, a separate
regression model was run in which the association between risk
estimates without the contribution of age or gender and motor
outcomes was examined to determine the role of other factors
in the algorithm. All analyses were performed in Stata V.12
(StataCorp, College Station, Texas, USA).
RESULTS
Two hundred eight participants were assessed at home between
October 2012 and September 2015. Four participants were
excluded in line with the exclusion criteria of the study (see
online supplementary material): one received lithium, two had
cognitive impairment (MoCA <22) and one had had a previous
stroke. Seven participants reported that they had been independ-
ently diagnosed with PD by neurologists during this period. All
seven of these subjects were also reviewed in person, and identi-
ﬁed as having PD by both raters on blinded video analysis.
These were excluded from all further analyses. Video recordings
were, therefore, scored and analysed from 197 participants.
The intraclass correlation coefﬁcient (ICC) for scores by raters
1 and 2 was 0.78 (95% CI 0.71 to 0.84) after the ﬁrst round. A
difference between raters of ≥5 points on the MDS-UPDRS
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occurred for 24 out of 197 subjects (12%). These were rescored
independently in round 2, resulting in an ICC of 0.86 (95% CI
0.81 to 0.89). After round 2, a difference between raters of ≥5
points still existed for 10 participants and these were scored
jointly (ﬁnal ICC 0.93; 95% CI 0.90 to 0.95). Measurements of
agreement and bias, as well as graphs, from the Bland-Altman
analysis are included in the online supplementary ﬁgure 2. Final
consensus scores for MDS-UPDRS ranged from 0 to 19. The
median global impression score was 0.5 (range 0–3.5) out of
maximum of 4. Examples of videos and handwriting from parti-
cipants with mild parkinsonism can be viewed in the
supplementary material (see online supplementary ﬁgures 3–5
and videos 1–3; risk status and other information on these indi-
viduals is not disclosed).
Risk estimates from year 1 follow-up surveys were available
for 185 participants. Median interval between the clinical
assessment and online surveys was 95 (IQR 37–168) days. The
median age of participants was 66.4 years (IQR 64.1–72.7); 94
were men and 91 were women. According to the pre-deﬁned
15th centile risk estimate cut-off, 74 participants were deemed
to be higher risk and the remaining 111 were lower risk (com-
bined middle and lowest risk). Higher risk participants that
were seen in-person had higher risk estimates and rankings, and
were more likely to be male or have a ﬁrst degree relative with
PD, than the higher risk participants that were not seen, but in
other aspects were comparable (see table 1). Lower risk partici-
pants that were seen in-person had lower risk estimates and
rankings, and were younger and more likely to be current
smokers than lower risk participants that were not seen, but in
other aspects were comparable. There were no signiﬁcant differ-
ences in intermediate outcomes (smell, subjective RBD and
ﬁnger tapping) between participants that were seen and those
that were not seen.
Comparison of higher and lower risk groups
Higher risk participants were signiﬁcantly more likely to have
motor impairment on the MDS-UPDRS and all derived scores
for MPS, compared with lower risk (see table 2). The median
MDS-UPDRS score in higher risk subjects was 3 (IQR 1.0–5.5)
and in lower risk subjects was 1 (IQR 0.0–3.0; p<0.001).
According to the deﬁnition of subthreshold parkinsonism by the
MDS Task Force (MDS-UPDRS >6 not including kinetic tremor
and postural tremor3), 13/74 (17.6%) higher risk compared
with 7/111 (6.3%) lower risk met the cut-off (p=0.027). For
MPS cut-offs (also derived from UPDRS) proposed by Louis
et al,19 the proportion was 31.1% higher risk and 10.8% lower
risk (p=0.001).
Using the ‘global impression’ score, three participants were
suspected to have undiagnosed PD (scores ≥3 occurred in 2.7%
of higher risk vs 0.9% of lower risk). Once they were excluded
from this speciﬁc analysis, 23.0% of higher risk subjects were sus-
pected to have subtle features of parkinsonism (scores ≥1.5 and
<3) compared with 6.3% of lower risk (p=0.001). Bradykinesia
(score ≥1.5 taking all body regions into account) was present in
22/74 (29.7%) of higher risk, compared with 17/111 (15.3%) of
lower risk (p=0.019). MoCA scores were slightly lower in
higher risk compared with lower risk participants, with 27 (IQR
26–28) and 28 (IQR 26–29) respectively (p=0.049). Finally, we
divided the lower risk group again into middle risk and lowest
risk (according to the 85th centile risk estimate), giving rise to 58
and 53 participants in each group respectively. The above ana-
lyses were repeated using the χ2 test for trend and conﬁrmation
Table 1 Demographic, intermediate marker and risk information on higher and lower risk participants seen in person compared with those that
were not seen
Higher risk seen Higher risk not seen
p Value
Lower risk seen Lower risk not seen
p Valuen 74 75 111 770
Age (95% CI) 72.2 (69.0 to 75.5) 70.8 (68.1 to 74.0) 0.252 64.9 (62.8 to 66.6) 67.1 (64.9 to 70.6) <0.001
Male gender (%) 63 (85.1) 54 (72.0) 0.072 31 (27.9) 243 (31.6) 0.511
First-degree relative (%) 36 (48.6) 22 (29.3) 0.019 9 (8.1) 107 (13.9) 0.100
Current smoker (%) 1 (1.4) 0 (0) 0.497 11 (9.9) 17 (2.2) <0.001
Past smoker (%) 38 (51.4) 31 (41.3) 0.252 51 (45.9) 293 (38.1) 0.119
Diabetes mellitus (%) 8 (10.8) 4 (5.3) 0.245 8 (7.2) 33 (4.3) 0.222
High cholesterol (%) 33 (44.6) 31 (41.3) 0.742 35 (31.5) 213 (27.7) 0.430
Ischaemic Heart disease (%) 13 (17.6) 11 (14.7) 0.662 3 (2.7) 31 (4) 0.791
Hypertension (%) 34 (45.9) 27 (36) 0.246 40 (36) 228 (29.6) 0.186
Drink coffee (%) 65 (87.8) 71 (94.7) 0.159 108 (97.3) 694 (90.1) 0.012
Drink alcohol (%) 67 (90.5) 66 (88) 0.792 101 (91) 674 (87.5) 0.351
Constipation (%) 22 (29.7) 29 (38.7) 0.301 17 (15.3) 113 (14.7) 0.776
Anxiety/depression (%) 14 (18.9) 15 (20) 0.999 13 (11.7) 87 (11.3) 0.873
Head injury (%) 36 (48.6) 36 (48) 0.999 26 (23.4) 218 (28.3) 0.309
Hyposmia ≤27/40 on UPSIT
(109 available)
13 of 56 (23.2%) 16 of 53 (30.2%) 0.666 (653 available) 8 of 88 (9.1%) 76 of 565 (13.3%) 0.307
Subjective RBD ≥5 on RBDSQ
(147 available)
18 of 75 (24.0%) 10 of 72 (13.8%) 0.141 (880 available) 14 of 112 (12.5%) 81 of 768 (10.5%) 0.513
Slow finger tapping KS ≤44 taps in 30 s
(124 available)
21 of 67 (31.3%) 12 of 57 (21.1%) 0.161 (749 available) 12 of 92 (13.0%) 100 of 657 (15.2%) 0.754
Risk estimate year 1 (IQR) 9.9 (6.9–15.1) 15.3 (12.3–18.2) <0.001 136.8 (54.3–207.3) 78.1 (48.2–118.7) <0.001
Rank year 1 (IQR) 54 (25–100) 103 (71–133) <0.001 860 (424–1001) 580 (373–784) <0.001
Information from survey answers in year 1. Hypertension defined according to self-report or use of diuretics, ACE inhibitors and angiotensin receptor blocking drugs, calcium channel
blockers, and beta blockers (including propranolol, atenolol, bisoprolol, but not sotalol or timolol). High cholesterol defined according to self-report or statin use. Diabetes mellitus
defined according to self-report or use of metformin, gliclazide or insulin.
UPSIT, University of Pennsylvania Smell Identification Test; RBDSQ, RBD screening questionnaire; KS, kinesia score.
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of a gradient across risk groups was observed for each MPS score
(see online supplementary table S2).
Association of risk estimates and MDS-UPDRS scores
In regression analysis, risk scores were signiﬁcantly associated
with MDS-UPDRS score (excluding action and postural tremor
as per MDS Task Force Criteria3). The increase in MDS-UPDRS
per doubling of risk (expressed as an odds) was 0.52 points
(95% CI 0.31 to 0.72; p<0.001; see table 3). Associations
adjusted for multiple cerebrovascular disease risk factors
remained statistically signiﬁcant (increase in MDS-UPDRS 0.52
points; 95% CI 0.30 to 0.74; p<0.001), as were associations
after adjustment for MoCA scores (0.56 points; 95% CI 0.30 to
0.83), and after adjustment for both together (0.58 points; 95%
CI 0.30 to 0.87). Risk scores that excluded age and gender
(crude and adjusted for vascular risk factors and MoCA scores)
were also strongly associated with MDS-UPDRS score
(p<0.001 for all analyses).
DISCUSSION
MPS may be observed in up to 40% of community dwelling
older persons and are associated with a range of negative health
outcomes. Analogous to mild cognitive impairment and demen-
tia, the features and determinants of deterioration from ‘mild’
to ‘clinically relevant’ impairment are poorly deﬁned, and most
unselected older people with MPS will not be subsequently
diagnosed with PD.21
Diagnosis is made when patients present to their doctor with
a constellation of physical signs that reliably predict the charac-
teristic pathological ﬁndings at postmortem (severe pars com-
pacta nigral cell loss with Lewy bodies).20 In retrospect many
patients and relatives report that subtle motor impairment may
have been present for several years before medical attention
was sought.5–7 Given that Lewy bodies are found in about
10% of brains of older individuals without a diagnosis of PD
at postmortem, it is likely that a substantial proportion of
individuals with MPS will however have been in the early
stages of PD.20
We have previously shown that older members of the UK
population, without any known neurological disease, could be
stratiﬁed online for future risk of PD as suggested by ‘intermedi-
ate markers’ of poorer smell and ﬁnger tapping, using objective
tests, and greater subjective RBD, as well as an increased risk of
future diagnosis of PD.13 16 22 We here present data that dem-
onstrate that this methodology also identiﬁes individuals with
MPS. MPS were deﬁned using a range of scoring methods with
varying stringency. Higher risk subjects were signiﬁcantly more
likely to have subtle motor signs, with higher MDS-UPDRS
scores, and a greater proportion exceeded cut-offs for MPS
deﬁned by the MDS Task Force, the MPS score by Louis et al,
and our own ‘global impression’ score.3 19 The higher propor-
tion of participants with MPS according to the deﬁnition by
Louis et al10 12 compared with the other criteria may be in part
due to our use of the MDS-UPDRS for scoring as opposed to
the original UPDRS (see methods and online supplementary
materials). The MDS-UPDRS is more sensitive to subtle changes
in movement, particularly those relating to repetitive movement
such as ﬁnger tapping. We also observed a greater proportion of
higher risk subjects (30%) with bradykinesia compared with
lower risk (15%).
MPS have been associated with increasing age, cognitive
impairment and cerebrovascular disease.21 The strength of asso-
ciation between estimated risk of PD and MDS-UPDRS in our
study tended to increase when age and gender were dropped
from the analysis and when analyses were adjusted for a com-
bination of vascular risk factors and MoCA scores, suggesting
that while age and gender are included in the algorithm, neither
these nor vascular risk factors nor mild cognitive impairment
are sufﬁcient to account for the association. Together these
results, given the strength of associations and the consistency
across criteria using blinded assessments, suggest that at least in
some higher risk subjects these MPS are a harbinger for future
PD rather than simply a form fruste or mimic driven by vascular
disease or mixed pathology.
Although seven patients with PD diagnosed independently
during study follow-up were excluded from the outset, the
‘global impression’ score and associated MDS-UPDRS scores for
three additional cases suggested that they may have been preva-
lent cases of undiagnosed PD. Excluding these three subjects did
not alter any of the results (note these are not the participants
depicted in the videos).
Other groups have identiﬁed MPS in volunteers with individ-
ual risk factors for PD. In the Bruneck Study Cohort, increasing
age, vascular risk factors, loss of olfactory function and hypere-
chogenicity in the region of the substantia nigra using transcra-
nial sonography were found to be predictive of MPS.23 In the
Table 2 Comparison of total motor MDS-UPDRS scores and MoCA
scores, and proportion of participants meeting three definitions of
mild parkinsonian signs, between higher and lower risk participants
Higher risk Lower risk
p Valuen 74 111
Median MDS-UPDRS (IQR) 3 (1.0–5.5) 1 (0.0–3.0) <0.001
Mild parkinsonism Berg definition
n (%)
13 (17.6%) 7 (6.3%) 0.027
Mild parkinsonism Louis definition
n (%)
23 (31.1%) 12 (10.8%) 0.001
Global impression n (%)
0–1.0 55 (74.3%) 103 (92.8%)
1.5–2.5 17 (23.0%) 7 (6.3%) 0.001
3+ 2 (2.7%) 1 (0.9%)
Median MoCA (IQR) 27 (26–28) 28 (26–29) 0.049
MDS-UPDRS, Movements Disorders Society Unified Parkinson’s Disease Rating Scale;
MoCA, Montreal Cognitive Assessment.
Table 3 Regression analysis for the association between risk
estimates and motor MDS-UPDRS scores (crude and adjusted)
Crude exposure Adjusted for
Increase in
MDS-UPDRS
per doubling
of odds 95% CI p Value
Log odds 0.52 0.31 to 0.72 <0.001
All vascular* 0.52 0.30 to 0.74 <0.001
MoCA 0.56 0.30 to 0.83 <0.001
All vascular*
and MoCA
0.58 0.30 to 0.87 <0.001
Log odds minus
age and gender
0.51 0.30 to 0.72 <0.001
All vascular* 0.54 0.31 to 0.76 <0.001
MoCA 0.55 0.28 to 0.82 <0.001
All vascular*
and MoCA
0.59 0.30 to 0.88 <0.001
*Vascular factors include diabetes mellitus, high cholesterol, heart disease,
hypertension, smoking.
MoCA, Montreal Cognitive Assessment.
Movement disorders
215Noyce AJ, et al. J Neurol Neurosurg Psychiatry 2017;88:212–217. doi:10.1136/jnnp-2016-314524
TREND study, olfactory deﬁcit, subjective RBD, male gender
and nigral hyperechogenicity were linked to MPS.24 Shulman
et al,25 used genotyping data to explore associations between
PD risk loci and MPS, ﬁnding associations between MAPT and
CCDC62 with global parkinsonism and bradykinesia speciﬁcally.
Separately, an analysis of a large series of volunteers without a
diagnosis of PD found an association between MPS elicited
during in life and neuronal loss in the nigra at postmortem, but
not Lewy body pathology, raising the possibility that neuronal
loss underlies these signs.26 Finally, Postuma et al,8 prospectively
demonstrated the gradual emergence of objective and rating
scale-derived features of PD in a cohort of participants with
idiopathic RBD, up to the point at which a proportion met
diagnostic criteria for parkinsonism. This study nicely showed
how MPS can evolve over time, but RBD represents a speciﬁc
model for prediagnostic PD, which may not be the same as the
course that most PD patients follow. To the best of our knowl-
edge, this is the ﬁrst time a composite PD risk score has been
used to identify probable MPS at the population level.
The magnitude and consistency of associations makes chance
an unlikely explanation for the results but as with other aspects
of the PREDICT-PD study, selection bias may have played a part
and we acknowledge that the proportion of subjects with a
family history of PD is higher than in the general population.
However, the frequency of a positive family history is not as
high as reported in the PARS study, and is similar to the
TREND study, despite the investigators more stringent deﬁni-
tions.27 28 Furthermore, while we excluded subjects with an
incident diagnosis of PD during follow-up, we cannot discount
that some of the participants may have taken part because they
suspected that they might have early signs of PD. Observer bias
would have been substantially reduced by blinding raters to par-
ticipant risk estimates. Good ICCs were obtained between the
two raters for participants included in the analysis, despite the
great difﬁculty in rating subtle features compared with well-
established parkinsonian features, and were excellent after con-
tentious cases were reviewed again. Likewise, agreement
between raters was also acceptable in Bland-Altman analyses.
ICCs were substantially better when PD cases were included,
which emphasises the fact that subtle parkinsonism can be hard
to detect (see online supplementary material). Finally, this cross-
sectional analysis of MPS may have been prone to measurement
error given recent evidence that MPS may be transient in the
early stages of PD.29
Taken together with earlier work showing an increase of
intermediate markers for PD (olfactory dysfunction, subjective
RBD, and slow ﬁnger tapping) in the higher risk group, we have
increasingly strong evidence to support enrichment for under-
lying risk of PD in PREDICT-PD.13 Future work in these parti-
cipants will seek to deﬁne the course of subtle parkinsonian
signs, their relationship with other symptoms in the prediagnos-
tic phase and those features that best predict future diagnosis
of PD.
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